{"id":"incretins","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T00:40:43.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06945419","phase":"PHASE1","title":"A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-23","conditions":"Healthy, Overweight, Obesity","enrollment":216},{"nctId":"NCT06930495","phase":"","title":"The Effect of Adiposity on Muscle and Microvascular Function in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-12-10","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":95},{"nctId":"NCT06037252","phase":"PHASE2","title":"A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-09-21","conditions":"Type 2 Diabetes, Obesity","enrollment":414},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07219173","phase":"PHASE2","title":"A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Asthma","enrollment":531},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT07392190","phase":"PHASE3","title":"A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-10","conditions":"Overweight, Obesity","enrollment":900},{"nctId":"NCT07165028","phase":"PHASE3","title":"A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":4500},{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","enrollment":2539},{"nctId":"NCT02363335","phase":"PHASE1","title":"The Role of Phosphodiesterase Inhibitors in Incretin Secretion","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2015-02-13","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT07095517","phase":"PHASE1","title":"Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":"Colorectal Cancer Prevention, Colorectal Adenoma","enrollment":20},{"nctId":"NCT06795360","phase":"NA","title":"Weight Changes After Incretin-mimetics","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-12-01","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":52},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":"Type 2 Diabetes, Overweight, ASCVD","enrollment":60000},{"nctId":"NCT07325500","phase":"PHASE2","title":"Incretin Microdosing for Cardiometabolic Health in People With HIV","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-02-12","conditions":"Weight Gain","enrollment":30},{"nctId":"NCT07411560","phase":"PHASE1","title":"A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-02-09","conditions":"Overweight, Obese","enrollment":100},{"nctId":"NCT07409831","phase":"NA","title":"Incretin-based Therapies, Nutrition, and Physical Activity","status":"NOT_YET_RECRUITING","sponsor":"Laval University","startDate":"2026-03","conditions":"Obesity & Overweight, Cardiometabolic Conditions","enrollment":120},{"nctId":"NCT02674893","phase":"PHASE4","title":"Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2014-02-04","conditions":"Type 2 Diabetes, Overweight","enrollment":48},{"nctId":"NCT07228741","phase":"PHASE2","title":"Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Acute Lymphoblastic Leukemia, Obesity","enrollment":20},{"nctId":"NCT07271043","phase":"NA","title":"Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics","status":"RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2026-01-01","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06630585","phase":"PHASE3","title":"GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Bern","startDate":"2025-02-14","conditions":"Type 1 Diabetes (T1D)","enrollment":42},{"nctId":"NCT06445075","phase":"PHASE2","title":"Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2024-05-21","conditions":"Overweight and Obesity","enrollment":102},{"nctId":"NCT06373146","phase":"PHASE2","title":"A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Obesity","enrollment":392},{"nctId":"NCT01851694","phase":"NA","title":"Beta-cell Response to Incretin Hormones in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2013-05","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":45},{"nctId":"NCT06881472","phase":"NA","title":"The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asger Lund, MD","startDate":"2025-01-01","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT06790225","phase":"NA","title":"Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)","status":"RECRUITING","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2025-11-10","conditions":"Bone Disease, Metabolic, Diabetes Mellitus, Type 2, Obesity and Obesity-related Medical Conditions","enrollment":12},{"nctId":"NCT07226947","phase":"NA","title":"Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-24","conditions":"Obesity, Body Composition","enrollment":100},{"nctId":"NCT06801015","phase":"PHASE4","title":"Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT07288372","phase":"","title":"The CGM-OGTT Glycemic Homeostasis Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2025-12-18","conditions":"Type 2 Diabetes, Glucose Metabolism Disorders","enrollment":225},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT06584916","phase":"PHASE3","title":"A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-09-13","conditions":"Obesity, Overweight","enrollment":376},{"nctId":"NCT02234349","phase":"NA","title":"Bile Acids and Incretins in Pancreas Kidney Transplant Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-09-05","conditions":"Pancreas-kidney Transplantation, Kidney Transplantation","enrollment":50},{"nctId":"NCT03407833","phase":"","title":"Physiologic and Functional Adaptations of Insulin Sensitive Tissues","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2018-02-13","conditions":"Diabetes, Insulin Resistance, Obesity","enrollment":500},{"nctId":"NCT07284511","phase":"PHASE2, PHASE3","title":"A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","status":"NOT_YET_RECRUITING","sponsor":"Melissa-Rosina Pasqua","startDate":"2026-01-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D","enrollment":105},{"nctId":"NCT06533527","phase":"PHASE4","title":"Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2024-07-31","conditions":"Diabetes Mellitus, Type 2, Obesity, Gastroparesis","enrollment":69},{"nctId":"NCT03860623","phase":"","title":"Effect of Oral Feeding on Gastric Emptying, Gut Blood Flow, and Hormone Responses in Obese and Healthy Weight Subjects","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2018-11-07","conditions":"Obesity","enrollment":20},{"nctId":"NCT06170905","phase":"NA","title":"Whey Protein Pre-load and Postprandial Glycemia in Pregnancy","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2024-02-01","conditions":"Pregnancy, Postprandial Glycemia","enrollment":21},{"nctId":"NCT07240246","phase":"NA","title":"Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults","status":"RECRUITING","sponsor":"FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","startDate":"2025-10-24","conditions":"GLP-1, Obesity &Amp; Overweight, Dietary Supplement","enrollment":40},{"nctId":"NCT07115069","phase":"","title":"Comparison of Body Composition Changes With Weight Loss Interventions","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-08-09","conditions":"Obesity","enrollment":60},{"nctId":"NCT06820281","phase":"PHASE2","title":"Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Garvan Institute of Medical Research","startDate":"2025-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT06923839","phase":"PHASE1","title":"Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oluf Pedersen","startDate":"2025-07-28","conditions":"Healthy Male Adults","enrollment":15},{"nctId":"NCT05260021","phase":"PHASE3","title":"A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-04-13","conditions":"Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":99},{"nctId":"NCT04255433","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":13299},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT01852448","phase":"","title":"Genetics of Insulin and Incretins in Cystic Fibrosis","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2013-05","conditions":"Cystic Fibrosis","enrollment":550},{"nctId":"NCT06124807","phase":"PHASE2","title":"A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-17","conditions":"Obesity, Overweight and Obesity","enrollment":179},{"nctId":"NCT05570435","phase":"NA","title":"Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2022-11-16","conditions":"Healthy, PreDiabetes, Adult","enrollment":31},{"nctId":"NCT03282136","phase":"PHASE4","title":"SGLT2i and Incretin and CRTd.","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2017-09-01","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":500},{"nctId":"NCT03919877","phase":"NA","title":"Precision Diets for Diabetes Prevention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2018-05-24","conditions":"Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT06959784","phase":"PHASE4","title":"Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)","status":"ENROLLING_BY_INVITATION","sponsor":"China-Japan Friendship Hospital","startDate":"2024-01-01","conditions":"Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease","enrollment":142},{"nctId":"NCT06950684","phase":"NA","title":"Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications","status":"NOT_YET_RECRUITING","sponsor":"Assuta Medical Center","startDate":"2025-07-01","conditions":"Obesity, Overweight (BMI > 25), Weight Loss","enrollment":180},{"nctId":"NCT06260722","phase":"PHASE3","title":"Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-02-21","conditions":"Diabetes Mellitus, Type 2","enrollment":1250},{"nctId":"NCT06431308","phase":"NA","title":"Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events","status":"RECRUITING","sponsor":"Ariel University","startDate":"2025-01-30","conditions":"Obesity; Drug","enrollment":120},{"nctId":"NCT06803888","phase":"PHASE4","title":"Bariatric Surgery vs. Semaglutide vs. Tirzepatide","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2025-01-29","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":125},{"nctId":"NCT06094894","phase":"NA","title":"Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2023-06-01","conditions":"GLP-1, Gut Microbiota, Insulin Resistance","enrollment":40},{"nctId":"NCT06487832","phase":"NA","title":"Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-07-01","conditions":"Normal Weight, Overweight and Obesity, Insulin Sensitivity","enrollment":60},{"nctId":"NCT06856291","phase":"","title":"Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","status":"RECRUITING","sponsor":"ETH Zurich","startDate":"2025-03-15","conditions":"Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance","enrollment":40},{"nctId":"NCT06734312","phase":"NA","title":"MAINTAIN (Mucosal AblatIoN Therapy After INcretins)","status":"RECRUITING","sponsor":"Dr. Christopher McGowan","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention","enrollment":20},{"nctId":"NCT05078255","phase":"NA","title":"The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Asger Lund, MD","startDate":"2022-01-27","conditions":"Type 2 Diabetes, Obesity","enrollment":61},{"nctId":"NCT03779048","phase":"PHASE4","title":"Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-07-15","conditions":"Obesity","enrollment":147},{"nctId":"NCT06671340","phase":"NA","title":"Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Elaine Chow","startDate":"2025-04-02","conditions":"Diabetes Mellitus, Prediabetes / Type 2 Diabetes","enrollment":30},{"nctId":"NCT06798220","phase":"NA","title":"Ultra-Processed Foods and Appetite Regulation: Acute Effects Across Body Mass Index Categories","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2024-05-01","conditions":"Healthy Adult Volunteers","enrollment":28},{"nctId":"NCT02844907","phase":"PHASE4","title":"Regulation of Insulin Secretion by the GLP-1 Receptor","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Insulin Secretion","enrollment":6},{"nctId":"NCT06143267","phase":"NA","title":"Neuronostatin - a Glucagonotropic Agent in Humans?","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2022-12-06","conditions":"Type 1 Diabetes, Hypoglycemia, Type1diabetes","enrollment":10},{"nctId":"NCT06137586","phase":"NA","title":"The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2022-08-10","conditions":"Type1diabetes, Hypoglycemia, Type 1 Diabetes","enrollment":10},{"nctId":"NCT04615546","phase":"NA","title":"Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-05-06","conditions":"Post-Bariatric Hypoglycemia","enrollment":60},{"nctId":"NCT06395246","phase":"NA","title":"Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs","status":"RECRUITING","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2024-05-20","conditions":"Obesity","enrollment":60},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02175459","phase":"","title":"Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2010-08","conditions":"GLUCOSE METABOLISM, DIABETES, PANCREATIC ISLETS","enrollment":100},{"nctId":"NCT06194955","phase":"NA","title":"The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2023-01-04","conditions":"Incretin Effect","enrollment":60},{"nctId":"NCT05162014","phase":"","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":494679},{"nctId":"NCT05306613","phase":"NA","title":"Breaking Sitting and Metabolic Health in Sedentary Lean Adults","status":"COMPLETED","sponsor":"National Taiwan Normal University","startDate":"2020-12-30","conditions":"Metabolic Health, Gut Hormones, Energy Balance","enrollment":13},{"nctId":"NCT05306678","phase":"NA","title":"Breaking Sitting and Metabolic Health in Sedentary Overweight and Obese Adults","status":"COMPLETED","sponsor":"National Taiwan Normal University","startDate":"2020-12-29","conditions":"Metabolic Health, Gut Hormones, Energy Balance","enrollment":13},{"nctId":"NCT06333132","phase":"NA","title":"Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)","status":"NOT_YET_RECRUITING","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2024-09-01","conditions":"Obesity, Diabetes Mellitus Type 2 in Obese","enrollment":45},{"nctId":"NCT00609154","phase":"PHASE1, PHASE2","title":"Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-08-12","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT06243536","phase":"PHASE4","title":"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2024-02-01","conditions":"Type 2 Diabetes, Overweight, Disordered Eating Behaviors","enrollment":60},{"nctId":"NCT03966261","phase":"","title":"The Role of Incretins in Bone Remodeling in Humans","status":"TERMINATED","sponsor":"University Hospital, Angers","startDate":"2020-03-10","conditions":"Incretins, Osteoporosis, Bone Remodeling","enrollment":104},{"nctId":"NCT02550548","phase":"PHASE1","title":"Incretin Action in Physiology and Diabetes","status":"COMPLETED","sponsor":"David D'Alessio, M.D.","startDate":"2016-04-21","conditions":"Insulin Secretion","enrollment":39},{"nctId":"NCT06064084","phase":"","title":"Incretin Effect in Patients With Psoriasis and Controls","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2011-09-11","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT05654805","phase":"NA","title":"Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2022-12-15","conditions":"Type 2 Diabetes, NAFLD","enrollment":92},{"nctId":"NCT02203240","phase":"NA","title":"Cocoa and Metabolic Health in Prediabetes","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2014-06","conditions":"Prediabetes","enrollment":16},{"nctId":"NCT06043245","phase":"NA","title":"Diabetes Remission and Hypoabsorptive Bariatric Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital Universitari de Bellvitge","startDate":"2023-06-21","conditions":"Severe Obesity, Diabetes Mellitus, Type 2, Bariatric Surgery Candidate","enrollment":66},{"nctId":"NCT04881760","phase":"PHASE2","title":"A Study of LY3437943 in Participants Who Have Obesity or Are Overweight","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-20","conditions":"Obesity, Overweight","enrollment":338},{"nctId":"NCT05947370","phase":"EARLY_PHASE1","title":"Berberine on the Secretion of Incretin","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2022-10-12","conditions":"Diabetes Mellitus","enrollment":16},{"nctId":"NCT04535960","phase":"PHASE2","title":"Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-01-24","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT05829018","phase":"NA","title":"Elucidating the High Cardiovascular Disease Risk in South Asians","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-04","conditions":"Cardiovascular Diseases","enrollment":48},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT05177653","phase":"NA","title":"Separate and Combined Extrapancreatic Effects of the Incretin Hormones","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2022-04-07","conditions":"Pancreatectomy; Hyperglycemia","enrollment":13},{"nctId":"NCT04889859","phase":"NA","title":"Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy","status":"COMPLETED","sponsor":"Kyungpook National University Chilgok Hospital","startDate":"2019-05-01","conditions":"Stomach Neoplasm, Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02671864","phase":"NA","title":"Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-11","conditions":"Type 2 Diabetes","enrollment":7200},{"nctId":"NCT03305783","phase":"","title":"The Influence of Cholecystectomy on Secretion of Incretin Hormones","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-11-01","conditions":"Glucose Metabolism Disorders","enrollment":40},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT04228484","phase":"NA","title":"The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2020-01-07","conditions":"Type2 Diabetes","enrollment":15},{"nctId":"NCT02921906","phase":"NA","title":"Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-06","conditions":"Neonatal Diabetes","enrollment":16},{"nctId":"NCT05154461","phase":"NA","title":"Intestinal Ketone Bodies Interfere With the Glycemic Control","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2021-12-05","conditions":"Healthy Adult Volunteers","enrollment":8},{"nctId":"NCT05446415","phase":"NA","title":"L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-02-05","conditions":"Severe Obesity, Type 2 Diabetes Mellitus in Obese","enrollment":20},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT02762708","phase":"PHASE2","title":"The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-03","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":12},{"nctId":"NCT03866421","phase":"","title":"NAFLD Among Patients With Chronic Kidney Disease and the Effect of Kidney Transplantation","status":"TERMINATED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-05-29","conditions":"Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases, PreDiabetes","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1803,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Incretins","genericName":"Incretins","companyName":"University of Campania Luigi Vanvitelli","companyId":"university-of-campania-luigi-vanvitelli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}